NDA 208743 · Radius
Tymlos
Abaloparatide · Subcutaneous · Parathyroid Hormone-Related Peptide Analog
NovelLast checked: Nov 20, 2026Latest source record: Aug 3, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2017
Apr 28, 2017
Approved uses
5
Original approval plus efficacy supplements
Registered trials
18
6 Phase 3, 1 recruiting
FAERS reports
31,042
5,492 serious, 327 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Aug 11, 2026.
TYMLOS is a human parathyroid hormone related peptide [PTHrP(1-34)] analog indicated for the: Treatment of postmenopausal women with osteoporosis at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy. ( 1.1 ) Treatment to increase bone density in men with osteoporosis at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy. ( 1.2 ) 1.1 Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture TYMLOS is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture (defined as a history of osteoporotic fracture or multiple risk factors for fracture), or patients who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, TYMLOS reduces the risk of vertebral fractures and nonvertebral fractures. 1.2 Treatment to Increase Bone Density in Men with Osteoporosis at High Risk for Fracture TYMLOS is indicated to increase bone density in men with osteoporosis at high risk for fracture (defined as a history of osteoporotic fracture or multiple risk factors for fracture), or patients who have failed or are intolerant to other available osteoporosis therapy.
Mechanism: Abaloparatide is a PTHrP(1-34) analog which acts as an agonist at the PTH1 receptor (PTH1R). This results in activation of the cAMP signaling pathway in target cells. Once-daily administration of abaloparatide stimulates new bone formation on trabecular and cortical bone surfaces by stimulation of osteoblastic activity. In rats and monkeys, abaloparatide had an anabolic effect on bone, demonstrated by increases in BMD and bone mineral content (BMC) that correlated with increases in bone strength at vertebral and/or nonvertebral sites [see Nonclinical Toxicology ( 13.2 )] .
Therapeutic areas: Endocrinology and women's health
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 19, 2022 Supplement 13 · Efficacy Label
- Dec 22, 2021 Supplement 10 · Efficacy Label
- Sep 20, 2021 Supplement 9 · Efficacy LabelLetter
- Oct 17, 2018 Supplement 3 · Efficacy LabelLetter
- Apr 28, 2017 Original approval · Type 1 - New Molecular Entity NovelLabelLetterReview
1 products under this application
- TYMLOS · ABALOPARATIDE 3.12MG/1.56ML (2MG/ML) · SOLUTION, SUBCUTANEOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Abaloparatide" as an intervention, any sponsor and status, largest first.
- Study to Evaluate the Safety and Efficacy of BA058 (Abaloparatide) for Prevention of Fracture in Postmenopausal WomenPivotal-lookingCompleted
Radius Health, Inc.Industry
NCT01343004 · 2,463 participants · Start Apr 2011 · Primary completion Oct 2014
Drug: Placebo; BA058 80 mcg and 1 more · For: Osteoporosis; Postmenopausal Osteoporosis
Sites: Lakewood, Colorado; Miami, Florida; North Miami, Florida · 28 sites in all
- Twenty-Four Month Extension Study of BA058-05-003 (Abaloparatide) in Participants With OsteoporosisPivotal-lookingCompleted
Radius Health, Inc.Industry
NCT01657162 · 1,139 participants · Start Nov 20, 2012 · Primary completion Oct 3, 2016
Drug: Alendronate · For: Postmenopausal Osteoporosis
Sites: Lakewood, Colorado; Hialeah, Florida; Bethesda, Maryland · 25 sites in all
- To Evaluate the Efficacy and Safety of Abaloparatide Injection (QLG2128) in the Treatment of Postmenopausal Women With Osteoporosis and at High Risk of FracturePivotal-lookingNot yet recruiting
Qilu Pharmaceutical Co., Ltd.Industry
NCT06898060 · 282 participants (planned) · Start Jun 2025 · Primary completion May 2027
Drug: QLG2128; Teriparatide Injection · For: Postmenopausal Women With Osteoporosis
- Phase 2 Study of BA058 (Abaloparatide) Transdermal Delivery in Postmenopausal Women With OsteoporosisPivotal-lookingCompleted
Radius Health, Inc.Industry
NCT01674621 · 250 participants · Start Sep 25, 2012 · Primary completion Aug 2, 2013
Drug: Abaloparatide Transdermal (50 mcg); Abaloparatide Transdermal (100 mcg) and 3 more · For: Post Menopausal Osteoporosis
Sites: Lakewood, Colorado; Atlanta, Georgia; Bethesda, Maryland · 9 sites in all
- Safety and Efficacy of Abaloparatide-SC in Men With Osteoporosis (ATOM)Pivotal-lookingCompleted
Radius Health, Inc.Industry
NCT03512262 · 228 participants · Start May 3, 2018 · Primary completion Aug 17, 2021
Drug: Abaloparatide; Placebo · For: Osteoporosis; Osteoporosis, Age-Related; Osteoporosis Localized to Spine and 3 more
Sites: Birmingham, Alabama; Greenbrae, California; Simi Valley, California · 34 sites in all
- Phase 2 Dose-finding Study to Evaluate the Effects of BA058 in the Treatment of Postmenopausal Women With OsteoporosisPivotal-lookingCompleted
Radius Health, Inc.Industry
NCT00542425 · 222 participants · Start Apr 2007 · Primary completion Jun 2009
Drug: teriparatide; Placebo and 3 more · For: Osteoporosis
Sites: Cambridge, Massachusetts
- Abaloparatide vs. Placebo in Post-Menopausal Women and Abaloparatide in Men Receiving Initial Spinal Fusion SurgeryActive, not recruiting
Hospital for Special Surgery, New YorkAcademic, hospital or other
NCT03841058 · 96 participants (planned) · Start Aug 14, 2019 · Primary completion Feb 2027
Drug: Abaloparatide; Placebo · For: Spinal Fusion
Sites: New York, New York
- Abaloparatide Added to Ongoing Denosumab vs Continued Denosumab AloneActive, not recruiting
Hospital for Special Surgery, New YorkAcademic, hospital or other
NCT04467983 · 70 participants (planned) · Start Feb 1, 2021 · Primary completion Sep 18, 2026
Drug: Denosumab Injection; Abaloparatide · For: Osteoporosis, Postmenopausal
Sites: New York, New York
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- headache5,459
- nausea4,169
- dizziness4,144
- fatigue3,666
- product dose omission issue2,863
- heart rate increased2,773
- arthralgia2,533
- palpitations2,380
- bone pain1,939
- pain1,687
- back pain1,641
- injection site bruising1,289
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2015 | 1 |
| 2016 | 3 |
| 2017 | 237 |
| 2018 | 2,958 |
| 2019 | 3,006 |
| 2020 | 1,727 |
| 2021 | 2,031 |
| 2022 | 2,039 |
| 2023 | 2,756 |
| 2024 | 3,634 |
| 2025 | 6,308 |
| 2026 | 6,342 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Tymlos (Abaloparatide)
2024 spending
$258M
Beneficiaries
16,530
88,564 claims
Per beneficiary
$15,586
$1,690.96 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $132,756,710 |
| 2021 | $137,835,466 |
| 2022 | $156,712,784 |
| 2023 | $197,623,448 |
| 2024 | $257,643,485 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Effectiveness and Safety of Treatments to Prevent Fractures in People With Low Bone Mass or Primary Osteoporosis: A Living Systematic Review and Network Meta-analysis for the American College of Physicians.
Ayers C, Kansagara D, Lazur B, et al. · Ann Intern Med 2023 · Systematic Review, Network Meta-Analysis
- Fracture risk reduction and safety by osteoporosis treatment compared with placebo or active comparator in postmenopausal women: systematic review, network meta-analysis, and meta-regression analysis of randomised clinical trials.
Händel MN, Cardoso I, von Bülow C, et al. · BMJ 2023 · Systematic Review, Network Meta-Analysis
- Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.
Miller PD, Hattersley G, Riis BJ, et al. · JAMA 2016 · Clinical Trial, Phase III, Multicenter Study
- ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis.
Bone HG, Cosman F, Miller PD, et al. · J Clin Endocrinol Metab 2018 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Efficacy of Pharmacological Therapies for the Prevention of Fractures in Postmenopausal Women: A Network Meta-Analysis.
Barrionuevo P, Kapoor E, Asi N, et al. · J Clin Endocrinol Metab 2019 · Research Support, Non-U.S. Gov't, Network Meta-Analysis
- Evidence for the cardiovascular effects of osteoporosis treatments in randomized trials of post-menopausal women: A systematic review and Bayesian network meta-analysis.
Seeto AH, Tadrous M, Gebre AK, et al. · Bone 2023 · Systematic Review, Research Support, Non-U.S. Gov't
Sponsor: Radius
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.